Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
  NCT02735707		 RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
  NCT02735707		 RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif -11% -16%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons